Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Msn Laboratories Private Ltd. R&D Center is managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The current prosecution profile shows 1 distinct examiner and 1 distinct art unit. This suggests a highly focused interaction with the patent office for its active filings, as all work is contained within a single technical unit. The use of 1 distinct examiner for the company's active matters indicates a lack of diversity in the current examination personnel assigned to its portfolio. This 1 distinct art unit focus means that the company's research and development outcomes are being evaluated by a specific pharmaceutical examination group.
NOLAN, JASON MICHAEL is the busiest examiner for the portfolio, with 1 busiest examiner pending office action. This examiner is handling the 1 pending office action total, which represents the full extent of the company's current examination workload. Since this 1 busiest examiner pending office action constitutes the entire active pipeline, the company's prosecution results are currently dependent on this single examiner's findings. This concentration simplifies the administrative tracking of the company's patent matters. All current legal responses are directed to NOLAN, JASON MICHAEL, who serves as the sole point of contact for the company's active matters.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NOLAN, JASON MICHAEL | 1 | 66.5% | -27.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18579826 | NOVEL PROCESS FOR THE PREPARATION OF 1-(2-{4-[(4-CARBAMOYLPIPERIDIN-1-YL)METHYL]- N-METHYLBENZAMIDO}ETHYL)PIPERIDIN-4-YL N-({1,1'-BIPHENYL}-2-YL)CARBAMATE | NOLAN, JASON MICHAEL | — |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18579826 | NOVEL PROCESS FOR THE PREPARATION OF 1-(2-{4-[(4-CARBAMOYLPIPERIDIN-1-YL)METHYL]- N-METHYLBENZAMIDO}ETHYL)PIPERIDIN-4-YL N-({1,1'-BIPHENYL}-2-YL)CARBAMATE | NOLAN, JASON MICHAEL | 1623 | §102§103 | Non-Final OA | — | Pending | Jan 16, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial